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Purpose: The number of gastrointestinal (GI) cancer survivors has been steadily increasing owing to early
diagnosis and improved cancer treatment outcomes. The quality of life (QoL) of cancer survivors can
provide distinct prognostic information and represent their functioning. This study aimed to investigate
the levels of symptoms, psychological distress, and QoL of GI cancer survivors, and identify factors
associated with QoL.
Method: A cross-sectional survey was conducted among 145 survivors of gastric or colorectal cancer in a
university-afﬁliated hospital, Seoul, South Korea. The questionnaire consisted of the M. D. Anderson
Symptom Inventory Gastrointestinal Cancer Module, Distress Thermometer, and brief version of the
World Health Organization Quality of Life Assessment Instrument. Quantile regressionwas used to assess
the associated factors of QoL. The 10th, 25th, 50th, 75th, and 90th conditional quantiles were considered.
Results: The most common symptoms were fatigue (24.9%), numbness or tingling (17.2%), feeling bloated
(17.2%), dry mouth (15.9%), and difﬁculty remembering (11.8%). Thirty-two percent (47/145) of the par-
ticipants reported severe distress. A level of symptoms was signiﬁcantly associated in the 10th and 25th
quantiles, representing poor QoL. Economic burden was a signiﬁcant inﬂuencing factor in all quantiles.
Conclusion: Our results indicate that high burden from symptoms might be associated with lower QoL in
GI cancer survivors, and higher economic burden from cancer treatment was associated with lower QoL.
These results suggest that symptom management and support for economic difﬁculties should be
included in the strategies to enhance the QoL of GI cancer survivors.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The number of cancer survivors has been steadily increasing due
to advances in early detection and improved cancer treatment
outcomes. In Korea, gastrointestinal (GI) cancer survivors account
for 34% of all cancer survivors. The prevalence rates of gastric and
colorectal cancers are relatively high (13.4% and 12.3% of all,
respectively), but the survival rate has risen to more than 70% (Oh
et al., 2016). As more people survive from cancer, the quality of life
(QoL) of cancer survivors has become the center of cancer
survivorship.
The QoL of cancer survivors represents their treatment experi-
ence, and physical and psychosocial functions; can be used toLtd. This is an open access article uidentify subgroups of patients who require further monitoring; and
guides approaches for patient-centered interventions after cancer
treatment completion (Trask et al., 2009). Recent studies have
suggested that QoL can provide distinct prognostic information as a
predictor of survival duration in various cancers (Kim et al., 2016;
Movsas et al., 2009). Movsas et al. (2009) reported that non-
small-cell lung cancer patients with lower QoL scores had an
approximately 70% higher mortality rate than those who with
higher scores.
Although most cancer survivors can maintain their levels of
physical, psychological, and social functions at a similar status as
that before cancer treatment, certain subgroups of survivors are
likely to be at risk of decreased QoL, even after more than 5 years
since cancer diagnosis and at a disease-free state (Lee et al., 2014).
Moreover, it was reported that the subjective overall health status
was poor in 41.3% and 31.5% of cancer survivors in Korea and thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2012). A study reported that colorectal cancer survivors had
worse health status and limited activity compared with their non-
cancer controls, and breast and prostate cancer survivors
(LeMasters et al., 2013), while other studies showed no signiﬁcant
difference in global QoL between Korean GI cancer survivors and
the general population (Bae et al., 2006).
Studies on factors associated with impaired QoL in GI cancer
survivors found that age, comorbidity, cancer recurrence, type of
surgery, and physical activity impacted QoL (Huang et al., 2007;
Rodriguez et al., 2015). Cancer-related symptoms and psychologi-
cal distress have also been associated with the QoL of cancer sur-
vivors (Russell et al., 2015; Yu et al., 2016). Patients who have
completed GI cancer treatments could experience symptoms
caused by surgery, including swallowing difﬁculty or feeling
bloated, and symptoms caused by chemo- or radiotherapy,
including diarrhea, urination or bowel dysfunction, sexual
dysfunction, or numbness or tingling (Kim et al., 2012; Phipps et al.,
2008; Russell et al., 2015). Among cancer survivors, 10e40% expe-
rience signiﬁcant and lasting psychological distress caused by fear
of recurrence, worries about health, physical change, social isola-
tion, or economic burden (Hoffman et al., 2009; Zabora et al., 2001).
These late effects may have a profound impact on the QoL of GI
cancer survivors.
Understanding factors associated with the QoL of GI cancer
survivors could be the ﬁrst step toward developing health pro-
motion interventions and helping to identify patients who would
be at risk of decreased functioning and then to prioritize delivery of
a customized care. Despite that the prevalence of GI cancer and
survival rates of patients with GI cancer have grown steadily, little is
known about the actual condition of the QoL among these patients.
Considering that the QoL of GI cancer survivors could be inﬂu-
enced by various factors, speciﬁc determinants that have strong
impacts on a certain QoL status should be identiﬁed in order to
provide more-effective and customized interventions, especially
identifying cancer survivors with high risks of impaired QoL. Most
studies have attempted to determine factors associatedwith QoL by
estimating effects on the mean with conventional least squares
regression methods. This analysis has a risk of sample selection
bias, which is generated from lack of representativeness, as results
are subject to the inﬂuence of outliers. For this reason, a more
detailed feature of covariate effects should be provided by esti-
mating conditional status to identify factors associated with the
QoL level by using a quantile regression method (Koenker and
Hallock, 2001).
In this study, we investigated levels of symptoms, psychological
distress, and QoL among GI cancer survivors and examined factors
that contribute to their QoL by using quantile regression.
2. Methods
2.1. Study design
This study used a descriptive and cross-sectional design, aimed
at investigating the relationships between symptoms, distress, and
QoL in GI cancer survivors and examining factors that impact QoL
depending on its level. This study was conducted with approval of
the institutional review board (IRB No. 4-2015-0723) of a
university-afﬁliated hospital in Seoul, South Korea.
2.2. Study population
We approached to the patients who visited colorectal cancer
clinics for their follow-ups after completing cancer treatments and
asked several questions for initial screening and intention toparticipate in survey between October 2, 2015eNovember 26, 2015.
The inclusion criteria were as follows: (1) survivors of gastric or
colorectal cancer who were off any cancer treatment such as sur-
gery, chemotherapy, or radiotherapy; (2) no evidence of cancer
recurrence or metastasis at the time of survey; (3) at least 20 years
old. Informed consent was obtained from all the participants. A
total of 151 patients participated in the survey and 6 of them were
excluded from analysis due to current undergoing cancer treatment
after medical record reviewing or incomplete responds. We
included 145 survivors of GI cancer in an analysis.
2.3. Measures
Information on demographic characteristics, disease-related
characteristics, symptoms, distress, and QoL was collected by us-
ing standardized questionnaires and a medical chart review.
2.3.1. Symptoms
The Korean version of the M. D. Anderson Symptom Inventory
Gastrointestinal Cancer Module was used to measure symptom
levels (Wang et al., 2010). This 24-item questionnaire contains 13
items on general symptoms, 5 items on GI symptoms, and 6 items
on interference. All item scores range from 0 to 10, with higher
scores indicating greater severity of symptoms and disturbance.
Scores of 5 indicate moderate to severe symptom severity in this
study. Cronbach's awas 0.80 in a previous study (Wang et al., 2010)
and 0.89 in this study.
2.3.2. Distress
To measure distress, the Korean version of the Distress Ther-
mometer developed by the National Comprehensive Cancer
Network was used (Network NCC, 2007). This measurement is a
single item rated from 0 to 10. Scores of 4 points indicate severe
distress.
2.3.3. Quality of life
QoL was measured by using the Korean version of the brief
World Health Organization Assessment Instrument (WHOQOL-
BREF) (The WHOQOL Group, 1998). This instrument is composed of
26 items with the following ﬁve subcategories: physical heath,
psychological, social relationship, environmental, and overall do-
mains. It uses a 5-point Likert scale ranging from 1 (never) to 5
(always) to rate each item, with higher scores indicating more
positive response, except for three reversed items. The total score
ranges from 26 to 130 points. Cronbach's a was 0.82 in this study.
2.4. Statistical analyses
The demographic and disease-related characteristics of the
participants were analyzed by using frequency, percentages,
means, and standard deviations. Symptoms, distress, and QoL were
estimated as means and standard deviations. Differences in
symptoms, distress, and QoL depending on the participants' char-
acteristics were analyzed by using the t-test and analysis of vari-
ance by conducting a Scheffe test for the post hoc analysis. A
quantile regression analysis was performed to identify inﬂuencing
factors according to QoL level. General multiple linear regression is
usually performed, focusing on the relationship between the
outcome and covariates of the ﬁxed mean value, not allowing
identiﬁcation of predictors depending on the variation of an
outcome variable if it shows a skewed distribution or has outliers.
This method has the limitation of searching determinants while
considering various characteristics of individuals in social science
research because it is difﬁcult to identify factors that inﬂuence a
certain status of outcome that is far from the mean (Austin and
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less sensitive to outliers in data, having coefﬁcient estimates that
are more robust than those from conventional linear regression,
which are characterized by overly low standard errors. When the
outcome does not follow normal distribution, quantile regression
provides more efﬁcient estimators (Petracci and Cavrini, 2013).
Therefore, a quantile regression method might make it possible to
investigate factors associated with speciﬁcally low or high values of
the phenomena being studied by the interest of the researcher. This
approach can be applied in the analysis of the impact of each in-
dependent variable depending on quantiles in heterogeneous
conditional distribution by estimating regression coefﬁcients
(Koenker and Hallock, 2001). The 10th, 25th, 50th, 75th, and 90th
conditional quantiles were considered in this study. The quantile
regression coefﬁcient estimates were obtained by performing
simultaneous quantile regressions. A p-value of <0.05 was
considered signiﬁcant for covariate selection. All analyses were
performed by using STATA version 13.0.Table 2
Level of symptoms, distress, and quality of life (N ¼ 145).
Variables M±SD moderate to severe
n(%)
Symptoms Number of Symptoms 4.83 ± 4.093. Results
The general characteristics of the study participants are shown
in Table 1. The mean age of the participants was 62.07 ± 10.79 years
(range, 32e84 years), and 67.6% of the participants were male.
Ninety-eight participants (67.6%) reported that they had a spouse
(married or co-habitant). Seventeen participants (11.7%) reported
that they perceived a high economic burden from treatment,
whereas 50 participants (34.5%) reported having little ﬁnancial
difﬁculty for treatment.
As for the disease-related characteristics of the participants, 50
(34.5%) were diagnosed with gastric cancer; 53 (36.6%), with colon
cancer; and 42 (29.0%), with rectal cancer. Most participants were
in stage III (50.3%) at diagnosis, and 97 (66.9%) received concurrent
chemotherapy after surgery. The mean period since treatment
completion was 39.23 ± 40.01 months (median, 26; range, 0e243).
Of the participants, 46.2% were within 2 years after ﬁnishing anyTable 1
Characteristics of participants (N ¼ 145).
Variables Categories n(%)
Age(yr) <65 87(60.0)
65 58(40.0)
Gender Male 98(67.6)
Female 47(32.4)
Spouse Yes 131(90.3)
No 14(9.7)
Education middle school 46(31.7)
High school 47(32.4)
college 42(29.0)
Occupation Employed 67(46.2)
Unemployed 76(52.4)
Economic burden of treatment High 17(11.7)
Moderate 69(47.6)
Low 50(34.5)
Diagnosis Gastric cancer 50(34.5)
Colon cancer 53(36.6)
Rectal cancer 42(29.0)
Stage Ⅰ 18(12.4)
Ⅱ 46(31.7)
Ⅲ 73(50.3)
Ⅳ 8(5.5)
Type of treatment Op only 19(13.1)
OpþCTx. 97(66.9)
OpþCTx.þRT 29(20.0)
Time since treatment completion <2 years 67(46.2)
2~5 years 40(27.6)
5 years 38(26.2)
Abbreviation: CTx, chemotherapy; Op, operation; RT, radiotherapy.type of treatment.
The participants' status of symptoms, distress, and QoL is shown
in Table 2. The mean symptom score was 18.99 ± 21.45 (range,
0e180), and the number of symptoms that the participants re-
ported they experienced was 4.83 ± 4.09 (range, 0e18). The most
common moderate to severe symptoms were fatigue (24.9%),
numbness or tingling (17.2%), feeling bloated (17.2%), dry mouth
(15.9%), and difﬁculty remembering (11.8%). The mean distress
score was 2.72 ± 2.49 (range, 0e10), with 47 (32.4%) of the par-
ticipants reporting severe distress. The mean QoL score was
96.03 ± 11.65 (range, 26e130). The QoL was composed of ﬁve
subcategories, namely physical health (mean ± SD [range]:
27.34 ± 4.13 [7e35]), psychological (22.07 ± 3.41 [6e30]), social
relationship (10.23 ± 1.91 [3e15]), environmental (29.57 ± 3.73
[8e40]), and overall QoL domains (6.83 ± 1.29 [2e10]).
The differences in status of symptoms, distress, and QoL ac-
cording to the participants' characteristics are shown in Table 3. The
score of symptoms statistically signiﬁcantly differed according to
cancer type. In the post hoc analysis, the gastric cancer group had a
higher symptom level than the colon cancer group. The distress
score was signiﬁcantly lower in the groups of females, high-school
graduates, those with colon cancer, those with stage I disease, and
those at 5 years and more since treatment completion than in the
other groups. In terms of QoL, those who perceived high economic
burden from treatment and those without a spouse showed
signiﬁcantly low scores.
The results of the quantile regression analysis of the possible
inﬂuencing factors of QoL are reported in Table 4. Higher cancer
stage at diagnosis was associated with decreased QoL, especially inSymptom score 18.99 ± 21.45
Fatigue 2.35 ± 2.53 46(24.9)
Numbness or tingling 1.88 ± 2.73 25(17.2)
Feeling bloated 1.55 ± 2.42 25(17.2)
Difﬁculty remembering 1.95 ± 2.32 17(11.8)
Dry mouth 1.76 ± 2.60 23(15.9)
Drowsy 1.28 ± 1.87 13(9.0)
Diarrhea 1.04 ± 2.21 14(9.6)
Disturbed sleep 0.96 ± 2.03 13(9.0)
Constipation 0.87 ± 1.95 13(9.0)
Sadness 0.86 ± 1.99 11(7.5)
Pain 0.80 ± 2.10 12(8.2)
Distressed 0.77 ± 2.10 11(7.5)
Lack of appetite 0.63 ± 1.88 11(7.5)
Change in taste 0.62 ± 1.81 9(6.2)
Shortness of breath 0.57 ± 1.55 8(5.5)
Nausea 0.46 ± 1.50 5(3.5)
Difﬁculty swallowing 0.37 ± 1.49 6(4.2)
Vomiting 0.27 ± 1.16 2(1.4)
Interference score 7.53 ± 12.14
Mood 1.41 ± 2.55 24(16.6)
General activity 1.36 ± 2.40 22(15.2)
Enjoyment of life 1.29 ± 2.57 14(9.7)
Relations with people 1.20 ± 2.49 20(13.8)
Walking 0.84 ± 2.02 15(9.4)
Work 0.79 ± 1.97 20(13.8)
Distress 2.72 ± 2.49 47(32.4)
Quality of life 96.03 ± 11.65
Overall 6.83 ± 1.29
Physical health 27.34 ± 4.13
Psychological 22.07 ± 3.41
Social relationships 10.23 ± 1.91
Environmental 29.57 ± 3.73
Note. Symptom, moderate to severe (5); distress, severe (4).
Table 3
Symptoms, distress, and quality of life (QoL) by characteristics of participants (N ¼ 145).
Variables Categories Symptoms Distress QoL
M±SD t or F
(p)
M±SD t or F
(p)
M±SD t or F
(p)
Age(years)
<65 21.04 ± 25.02 1.71 2.86 ± 2.58 0.72 96.56 ± 11.84 0.66
65 15.44 ± 14.26 (0.090) 2.56 ± 2.34 (0.475) 95.27 ± 11.41 (0.512)
Gender
Male 17.64 ± 22.28 0.89 3.06 ± 2.67 2.53 95.57 ± 10.19 0.62
Female 21.02 ± 19.62 (0.373) 2.08 ± 1.91 (0.013*) 96.98 ± 14.21 (0.541)
Spouse
Yes 18.28 ± 21.86 0.82 2.77 ± 2.56 0.69 96.69 ± 10.97 2.11
No 23.21 ± 16.86 (0.415) 2.43 ± 1.65 (0.497) 89.86 ± 15.88 (0.036*)
Education
middle schoola 19.45 ± 20.11 0.15 2.79 ± 2.41 3.92 94.28 ± 11.28 0.68
High schoolb 17.35 ± 16.97 (0.863) 2.17 ± 2.04 (0.022*) 95.67 ± 12.82 (0.510)
collegec 19.33 ± 24.88 3.60 ± 2.68 b<cy 97.14 ± 10.51
Occupation
Employed 18.72 ± 24.60 0.08 2.64 ± 2.42 -0.33 97.58 ± 9.66 1.62
Unemployed 18.42 ± 17.72 (0.935) 2.78 ± 2.50 (0.745) 94.49 ± 12.80 (0.109)
Economic burden of treatment
Higha 20.29 ± 16.91 0.08 2.71 ± 2.49 0.25 83.06 ± 12.19 16.86
Moderateb 18.33 ± 20.09 (0.926) 3.01 ± 2.53 (0.782) 95.30 ± 10.26 (<0.001**)
Lowc 19.44 ± 23.65 2.72 ± 2.39 99.74 ± 9.48 a<b,cy
Diagnosis
Gastric cancera 25.00 ± 27.93 3.76 3.16 ± 2.78 3.18 94.28 ± 11.54 1.29
Colon cancerb 13.80 ± 14.87 (0.026*) 2.07 ± 2.21 (0.045*) 97.91 ± 11.23 (0.279)
Rectal cancerc 17.68 ± 17.91 a > by 3.10 ± 2.30 b < a,cy 95.71 ± 12.22
Stage
Ⅰa 11.44 ± 21.60 0.92 1.56 ± 2.04 3.95 99.83 ± 15.21 1.01
Ⅱb 21.35 ± 23.25 (0.431) 3.63 ± 2.89 (0.010*) 94.59 ± 10.98 (0.390)
Ⅲc 18.90 ± 20.74 2.44 ± 2.19 a<by 95.74 ± 10.97
Ⅳd 19.00 ± 15.21 3.00 ± 2.00 98.50 ± 12.56
Type of treatment
Op only 13.00 ± 22.59 0.79 1.58 ± 2.10 2.55 99.95 ± 11.29 2.15
OpþCTx. 19.60 ± 21.63 (0.457) 2.86 ± 2.59 (0.082) 96.20 ± 11.11 (0.121)
OpþCTx.þRT 19.72 ± 20.06 3.10 ± 2.21 92.93 ± 13.10
Time since treatment completion(years)
<2a 21.51 ± 23.90 2.03 3.16 ± 2.36 6.61 94.24 ± 10.16 1.77
2e5b 19.70 ± 19.59 (0.135) 3.18 ± 2.50 (0.002**) 96.63 ± 12.99 (0.173)
5c 12.92 ± 17.71 1.53 ± 2.33 a,b > cy 98.58 ± 12.37
yPost-hoc: Scheffe test, *p < 0.05; **p < 0.01.
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impaired QoL, and the association was signiﬁcant for the 10th and
25th percentiles of QoL, with coefﬁcients equal to 0.18 and 0.17,
respectively. The magnitude of this association tended to increase
in the lower QoL quantiles. A high economic burden from cancer
treatment was certainly an important aspect to consider. It was
found to be signiﬁcantly associated with impaired QoL across the
overall quantiles considered, having a greater effect on the higher
outcome distribution.
4. Discussion
This study demonstrated that symptom burden was signiﬁ-
cantly associated with lower QoL levels and that economic burden
was associated with all QoL levels in GI cancer survivors by using a
quantile regression method.
By comparing the QoL levels of our participants with those of
Korean non-cancer populations in previous studies (Jang et al.,
2013; Choi et al., 2012), we found that the GI cancer survivors
had higher QoL than the general population. Even though results
have remained inconsistent, this ﬁnding might reﬂect that patients
who survive from cancer usually report a more positive assessment
of their QoL by recognizing a changed concept of well-being and
meaning of posttraumatic growth (Yun et al., 2014). Continuous
health management such as lifestyle changes followed by limita-
tions of physical and role functions is required after cancertreatment, like in other chronic diseases. However, it may cause
relatively high satisfaction for life because survival from cancer
could lead to the possibility of complete recovery. Thus, helping
cancer survivors perceiving their disease experience as an inward
growth according to a positive concept by recovering function and
improving QoL would be important.
Gastric or colorectal cancer itself and treatments are likely to
cause various late effects such as bowel, urinary or sexual
dysfunction, diet restriction, or body image disturbance, which
require alterations in diet, work, and social relationships even after
5e10 years since cancer diagnosis and have considerable negative
impacts on social and occupational functioning (Bailey et al., 2015;
Kim et al., 2012). These results indicate that screening for in-
dividuals at risk of impaired QoL is still needed during a consider-
able period since cancer treatment completion.
We found that a level of symptoms was signiﬁcantly associated
with impaired QoL for the 10th and 25th quantiles in this study.
That is, QoL was signiﬁcantly lower in the group with a higher
symptom level than in the group with a lower symptom level. We
could not ﬁnd any study that applied quantile regression and re-
ported symptom status as a speciﬁc inﬂuencing factor of certain
quantiles of QoL. However, recent studies suggest that symptoms
cancer survivors are experiencing provided considerably relevant
information on their QoL (Kim et al., 2012; Phipps et al., 2008).
Fatigue, the most common symptom in the present study, is
highly prevalent among cancer survivors, regardless of cancer
Table 4
Quantile regression analysis on the inﬂuencing factors of quality of life (QoL).
Covariates QoL
10% 25% 50% 75% 90%
Coefﬁcient
(95% CI)
Age 0.16
(0.54 to 0.22)
0.17
(0.25 to 0.09)
0.19
(0.47 to 0.08)
0.25*
(0.44 to 0.05)
0.17
(0.42 to 0.08)
Gender
Female 2.79
(3.35 to 8.93)
2.48
(2.81 to 7.76)
1.56
(1.69 to 4.81)
3.67
(0.53 to 7.88)
4.52
(3.48 to 12.52)
Marital status
Yes 14.48
(1.00 to 29.95)
5.81
(5.60 to 17.22)
7.25
(1.25 to 15.75)
4.47
(8.23 to 17.16)
2.57
(8.15 to 13.30)
Economic burden of Treatment
Moderate 2.10
(11.43 to 7.24)
5.54
(12.84 to 1.76)
5.75**
(9.61 to 1.89)
6.18**
(10.50 to 1.86)
9.09**
(14.77 to 3.41)
High 16.37*
(33.68 to 0.93)
16.75**
(25.65 to 7.86)
17.99**
(27.04 to 8.94)
15.06**
(25.94 to 4.18)
18.75**
(28.82 to 8.68)
Cancer type
Colon cancer 5.17
(13.32 to 2.97)
0.43
(7.05 to 7.91)
3.19
(4.21 to 10.59)
4.81
(0.20 to 9.81)
4.01
(4.38 to 12.39)
Rectal cancer 1.31
(10.73 to 13.36)
8.51
(4.30 to 21.33)
3.08
(5.34 to 11.50)
1.51
(5.50 to 8.52)
2.10
(9.19 to 13.40)
Stage
Ⅱ 8.83
(7.86 to 25.52)
0.53
(14.83 to 13.77)
5.17
(13.85 to 3.50)
8.73
(21.78 to 4.31)
24.26*
(44.77 to 3.75)
Ⅲ 5.47
(8.27 to 19.21)
1.06
(15.30 to 13.18)
5.04
(14.47 to 4.38)
7.97
(21.59 to 5.65)
23.82*
(45.90 to 1.74)
Ⅳ 12.29
(4.95 to 29.54)
6.97
(25.03 to 11.10)
9.39
(24.12 to 5.34)
7.19
(21.81 to 7.42)
27.55*
(54.69 to 0.42)
Type of treatment
OpþCTx. 0.47
(14.82 to 13.88)
2.22.
(10.94 to 15.39)
4.16
(3.13 to 11.44)
6.19
(6.13 to 18.51)
11.50
(13.74 to 36.74)
OpþCTx
þRT
2.20
(18.82 to 14.41)
7.09
(24.07 to 9.89)
3.19
(12.07 to 5.68)
6.94
(7.57 to 21.45)
12.02
(12.78 to 36.82)
Time since treatment completion
2~5 years 2.17
(4.81 to 9.15)
0.02
(7.39 to 7.44)
1.09
(3.27 to 5.45)
2.76
(1.74 to 7.25)
4.07
(1.77 to 9.91)
5 years 5.39
(6.34 to 17.13)
2.05
(7.78 to 11.10)
2.07
(2.69 to 6.84)
1.21
(3.71 to 6.13)
1.15
(6.49 to 8.80)
Symptoms 0.18**
(0.29 to 0.06)
0.17**
(0.25 to 0.09)
0.12
(0.23 to 0.00)
0.06
(0.17 to 0.04)
0.09
(0.17 to 0.34)
Distress 1.13
(2.60 to 0.34)
0.94
(1.93 to 0.05)
0.53
(1.42 to 0.36)
0.69
(1.59 to 0.22)
1.05
(2.70 to 0.60)
Constant 81.98
(56.09 to 107.86)
96.08
(70.66 to 121.49)
109.89
(90.93 to 128.85)
117.87
(96.63 to 139.11)
129.05
(103.62 to 154.49)
Note. Reference variables: Male(for gender); No(for marital status); Low(for economic burden for treatment); Gastric cancer(for cancer type); Ⅰ(for stage); Op only(for type of
treatment); <2 years(for time since treatment completion), *p < 0.05; **p < 0.01.
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experience fatigue have been conducted because of the severe
impact of fatigue on the daily life, social functioning, and QoL of
these patients. Exercise on ﬁtness or cognitive behavioral therapy
has been suggested as an effective intervention (Kampshoff et al.,
2015; Willems et al., 2017). Among the symptoms that the partic-
ipants complained of, numbness or tingling, feeling bloated and
difﬁculty remembering are more disease- or treatment-speciﬁc
than fatigue. In particular, peripheral neuropathy is induced by
platinum compounds known as standard agents for chemotherapy
for gastric and colorectal cancers, such as oxaliplatin and cisplatin.
According to Mols et al. (2013), chemotherapy-induced peripheral
neuropathy (CIPN) was reported even 2e11 years after diagnosis of
colorectal cancer, and the symptoms had a negative effect on the
daily functioning and, subsequently, the QoL of cancer survivors
(Mols et al., 2013). Although treatment and prevention of CIPN
remain difﬁcult, pharmacological interventions such as duloxetine
and non-pharmacological approaches with physical activities or
Scrambler therapy (noninvasive cutaneous electrostimulation)
have been used to help patients improve their physicalperformances (Pachman et al., 2015; Smith et al., 2013; Wickham,
2007). As cancer survivors experience different symptoms ac-
cording to their cancer type and treatment, intervention strategies
should be tailored with cancer- or treatment-speciﬁc approaches.
In addition, education about the high risk of developing late
symptoms should be provided to patients prior to cancer treat-
ment, which can help survivors predict and manage their symp-
toms. The need for information about managing side effects or
complications of treatment ranked high among cancer survivors
(Russell et al., 2015). Providing information in the supportive care
continuum impacts the reduction of symptom experience and in-
crease in knowledge, which would improve QoL. For example, ed-
ucation about breast cancer-related lymphedema helped survivors
have fewer symptoms and remained as a predictor of better
symptom outcomes (Fu et al., 2010). Symptom experience might be
recognized as an inevitable consequence of cancer treatment, but
education on symptom management is important because various
late effects could hinder the recovery to the state before the cancer
diagnosis.
Cancer survivors who continue to experience cancer-related
S. Ahn et al. / European Journal of Oncology Nursing 30 (2017) 15e2120symptoms are more likely to have concerns about the disease and
their overall health status, as well as anxiety or depression, which
could cause secondary health problems. These problems have been
reported to affect expenditure in accordance with the use of
medical resources and impact the economic burden throughout the
cancer survivorship trajectory (Han et al., 2014). Therefore, the
issue of symptoms is likely to be connected to ﬁnancial difﬁculty,
considering problems on rehabilitation in society and recovery of
economic functioning.
We also found that economic burden from cancer treatment was
associated with a decreased QoL across all the quantiles. That is, a
higher perceived economic burden was negatively associated with
impaired QoL regardless of the level. This result is consistent with
that of previous research that showed that the lower the socio-
economic level, the lower the awareness of QoL or subjective health
status (Zafar et al., 2015). Cancer survivors continue to experience
difﬁculties due to the economic impact of reduced socioeconomic
activity or problem of returning towork in addition to the burden of
medical expenses in cancer treatment (Han et al., 2014). The co-
morbid condition and poor health status could contribute to the
unemployment of cancer survivors, losing their jobs related to
treatment, and discrimination in the workplace. Furthermore,
cancer survivors who experienced economic burden from treat-
ment were less likely to adhere to medical care than those without
economic burden (Kent et al., 2013). It may cause a vicious circle on
survivorship by expanding medical cost and secondary health
problems. Multidisciplinary rehabilitation of cancer survivors to
prevent and improve impairment has been suggested as an inter-
vention that may positively impact patients' ability to return to
work, in turn reducing the economic burden of cancer on in-
dividuals, their families and society in general (Silver et al., 2013).
To overcome the poor long-term survival in the advanced stage,
the development of targeted therapy and immunotherapy has been
rapidly progressing in the area of GI cancer treatment. The
advancement of the new approaches has been accompanied with
absolutely high treatment cost. This may cause a greater increase in
economic burden than conventional therapies. Considering the
political aspects of cancer survivor management, both a systematic
and efﬁcient interventionmodel and ﬁnancial support are required.
Even though economic burden is not identiﬁed well in the clinical
setting, the implication of economic burden on survivorship care
needs to be understood by using a validated measurement for pa-
tient report, engaging patients actively in the decision making
process for care, and providing information on the cost of care
(Zafar et al., 2015).
It is interesting that our results suggest that cancer stage at
diagnosis was associated with QoL in the 90% quantile group. A
previous study reported that regional, distant, or unstaged/un-
known stage was progressively associated with a very low physical
component of QoL in the 10% percentile of QoL among colorectal
cancer survivors (Adams et al., 2016). Cancer survivors with higher-
stage disease are vulnerable to more-severe symptoms owing to
massive treatments and the advanced disease itself, which are
important factors of QoL status. As the underlying reasons for an
association between cancer experience and QoL among cancer
survivors may be speciﬁc not only to the physical component but
also to the social or psychological component, more research would
be necessary to understand the different aspects of QoL between
early and advanced stage cancer.
Cancer survivors are also more likely to be vulnerable to psy-
chological distress such as anxiety and depression, which affect
daily activities, than the non-cancer population (So et al., 2009).
Fear of recurrence and poor self-perception of health status have
been identiﬁed as important risk factors of psychological distress
(Choi and Park, 2016; Custers et al., 2016). Persistent psychologicaldistress is likely to have long-term harmful consequences on cancer
survivors' health management and survival (Choi and Park, 2016).
Unlike other studies, however, this study did not identify distress as
a predictor of QoL at any quantile. The reason could be the inade-
quate number of sample for detection of the impact of distress level
on QoL, or the nature of voluntary survey participation might have
prevented patients with severe distress to be included in this study.
In addition, awareness that gastric and colorectal cancers are
known in public as successfully curable diseases with high survival
rates in Korea might reduce the inﬂuence of distress on a certain
QoL level. Future studies need to examine cancer survivor groups
that are vulnerable to psychological distress with impaired QoL.
This study has several limitations. First, the result should be
carefully interpreted because this study assessed gastric and colo-
rectal cancer survivors at a university-afﬁliated hospital in Korea.
Second, it is likely that we missed the disease-speciﬁc facet of QoL
because we used theWHOQOL-BREF, which focused on the general
population, considering that the subjects were not cancer patients
but survivors. Third, in terms of the measured variables, social
support, which has been found as a main factor that affected QoL in
previous studies, was not included in the questionnaire. Further
investigations with larger populations and a longitudinal study
design in GI cancer survivors from multiple sites are needed to
conﬁrm the diverse contribution of factors of QoL according to the
cancer survivorship trajectory. Nevertheless, the study is signiﬁ-
cant, as it is the ﬁrst trial that used a quantile regression method to
provide information for identifying speciﬁc factors that affect the
QoL level of GI cancer survivors. These ﬁndings are also applicable
to the development of intervention programs to enhance the QoL of
cancer survivors, considering the circumstance of individual
patients.5. Conclusion
Our results indicate that a level of symptoms is a signiﬁcant
factor of impaired QoL in the lower QoL group. In addition, patients
with higher economic burden may be more vulnerable to poorer
QoL, regardless of the QoL level. This ﬁnding suggests a need for
symptom management to enhance the QoL of GI cancer survivors.
In particular, reducing the symptom experience in the clinical
setting is needed for cancer survivors with lower QoL, which can
lead to improvement in QoL. Furthermore, perceived economic
burden was also an important determining factor of QoL. Thus,
ﬁnancial support and plans for an enhanced work environment, as
well as medical support, should be considered in cancer survivor-
ship plans so that cancer survivors can return and readopt easily to
society. Further research for the development and effectiveness
evaluation of various interventions to improve the QoL of GI cancer
survivors is also needed.Conﬂict of interest
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